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ABSTRACT
Objective: The purpose of this study was to compare the efficacy of a 3-day course of doxycycline
to a standard 7-day course for treating uncomplicated chlamydia cervicitis.
Methods: During an 18-month period, 77 women with uncomplicated chlamydia cervicitis were
randomized to receive either a 3-day or a 7-day course of doxycycline (100 mg twice daily). Tests
of cure were performed 3 weeks after completion of therapy with the Amplicor polymerase chain
reaction (PCR) assay (Roche Molecular Systems, Branchburg, NJ). Demographics, therapeutic
results, and side effects for the two groups were compared.
Results: Seventy-three patients completed the study: 35 in the 3-day group and 38 in the 7-day
group. There were no significant differences in age, gravidity, or parity between the groups. There
was a 94% (33/35) cure rate in the 3-day group and a 95% (36/38) cure rate in the 7-day group (P
1.0). Thirty-four percent and 32% of the patients in the 3- and 7-day groups reported side effects,
respectively; there was no significant differences between the 3- and 7-day groups in regard to
population demographics, patient compliance, therapeutic outcome, or side effects.
Conclusions: A 3-day course of doxycycline appears to be as effective as a 7-day course of
doxycycline for the treatment of uncomplicated chlamydia cervicitis. Infect. Dis. Obstet. Gynecol.
5:18-22, 1997. (C) 1997 Wiley-Liss, Inc.
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hplamydia
trachomatis is the most common re-
ortable sexually transmitted disease in the
United States, with 3-5 million new cases esti-
mated each year. The majority of genital chlamyd-
ial infections are asymptomatic in women but can
result in pelvic inflammatory disease, ectopic preg-
nancy, and infertility. Research on chlamydial in-
fections has been concentrated on diagnostic test-
ing rather than development of new therapeutic
options mainly because no significant antimicrobial
Presented at the 1996 ACOG Annual Meeting, Denver, CO.
Contract grant sponsor: Scott, Sherwood, Brindley Foundation, Temple, TX.
*Correspondence to: Dr. Mark B. Reedy, Department of Obstetrics and Gynecology, Scott & White Clinic, 1600 University
Drive East, College Station, TX 77840.
Clinical Symposium
Received 20 September 1996
Accepted 3 March 19973-DAY COURSE OF DOXYCYCLINE REEDYET AL.
TABLE I. Exclusion criteria
Pregnancy
Fever (> 100.4F)
Uterine or adnexal tenderness or a pelvic mass noted on
examination
<18 years of age without consent of a parent or guardian
Antibiotic treatment of any kind since positive chlamydia test
Allergy to tetracycline or doxycycline
Patients attempting to conceive or using an unreliable form of
birth control
Patients who cannot be easily contacted for follow-up (i.e., do
not have a home or work telephone number)
Currently using an intrauterine device for birth control
resistance has been demonstrated against standard
treatmentmthe tetracyclines.
The 1993 Center for Disease Control (CDC)
recommendation for the treatment of chlamydial
cervicitis is 100 mg of doxycycline given orally
twice daily for 7 days or azithromycin (Zithromax(R),
Pfizer, Groton, CT) g orally in a single dose. z
Currently, the authors’ clinic pharmacy charges
$25.90 for g of azithromycin and $5.30 for a 7-day
course of doxycycline.
In 1985, the CDC stated that the treatment rec-
ommendation for chlamydia had a considerable po-
tential for patient noncompliance.3 Cramer et al.4
demonstrated that the level of compliance deterio-
rates the longer the course of therapy. A shorter
therapeutic regimen would improve patient com-
pliance and be more cost effective. This was re-
cently demonstrated in the treatment of urinary
tract infections,s
The purpose of this study was to compare a
3-day course of doxycycline to a 7-day course for
the treatment of uncomplicated chlamydia cervici-
tis.
SUBJECTS AND METHODS
A prospective, randomized, open-labeled study was
performed. Nonpregnant women in a multispe-
cialty clinical setting with cervical swabs positive
for chlamydia by polymerase chain reaction (PCR)
assay (Amplicor PCR(R), Roche Molecular Systems,
Branchburg, NJ) were eligible for the study. Paren-
tal consent was required for patients under 18 years
of age. Study enrollment required the patient to be
afebrile and have a normal pelvic examination. In-
formed consent was obtained. Exclusion criteria
are listed in Table 1.
A total of 77 nonpregnant women with uncom-
plicated Chlamydia trachomatis cervicitis were ran-
domized into 2 treatment arms. Group 1 received
the standard CDC-recommended treatment con-
sisting of 100 mg doxycycline twice daily for 7 days.
Group 2 received 100 mg doxycycline twice daily
for 3 days. A central office allocated patients by
computer-generated randomization schedule.
Patients were treated free of charge. Sexual part-
ners were also offered the standard 7-day course of
doxycycline free of charge. Patients were asked to
refrain from intercourse with their partner until
they had completed their medication. If the patient
missed a menstrual cycle or was not practicing a
reliable form of contraception (i.e., oral contracep-
tives, tubal ligation, Norplant(R), Depo-Provera(R)), a
serum pregnancy test was performed. If a coexist-
ing cervical infection with Neisseria gonorrhoeae was
present, patients were treated with 250 mg of in-
tramuscular ceftriaxone.
Each patient returned approximately 3 weeks
after completion of their medication. At the follow-
up appointment, a cervical swab was obtained for
chlamydia PCR assay, and each patient was asked
questions from a post-treatment questionnaire. Pa-
tients received a $30.00 stipend when they re-
turned for the follow-up visit.
The post-treatment questionnaire consisted of
the following questions: 1) How many pills did you
take? 2) Did you have any side effects, i.e., vomit-
ing, headache, diarrhea, stomachache, and did you
take the medicine with food? 3) Did your partner
take all of his medicine? If not, how many pills did
he take? 4) Did you have intercourse with your
partner or anyone else since your enrollment into
the study?
All data forms and questionnaires were for-
warded to a central site to be inventoried and en-
tered into an established data management system.
Data collection forms were checked for inconsis-
tencies and missing values by a computerized edit-
checking system. Any inconsistencies were re-
ported to the investigator for correction or verifica-
tion. Summary and descriptive statistics for all
baseline variables were performed using SAS soft-
ware package (Cary, NC). Comparisons between
study groups were done using the Student’s t-test
or chi-square analysis on the appropriate demo-
graphic variables. Adherence to the prescribed
treatment within each group was assessed by per-
forming pill counts. Incidence of side effects was
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 193-DAY COURSE OF DOXYCYCLINE REEDYET AL.
TABLE 2. Description of 4 treatment failures
Age All medicine
Regimen (years) Gravidity/parity taken?
Side
effects?
Medicine Partner
with take all Follow-up
food? medicine? Intercourse? (weeks)
3 day 19 0/0 Yes
14 0/0 No (only 5)
7 day 16 0/0 Yes
30 0/0 Yes
No
No
No
No
Yes Yes Yes 2.0
No No (only 2) Yes 3.1
Yes No (none) Yes 7.
Yes Yes No 3.0
compared between groups by chi-square analysis or
Fisher’s exact test, as appropriate. The primary
outcome, efficacy, was defined as the number of
negative tests of cure per group divided by the total
number of patients who completed the study treat-
ment. These proportions were analyzed using chi-
square test.
Power analysis performed prior to the study de-
termined that a sample size of 35 patients in each
group would detect a 25% difference in efficacy of
cure with 80% power and a 0.05 level of signifi-
cance.
RESULTS
During an 18-month interval, 77 women were ran-
domized to receive either a 3- or 7-day course of
doxycycline. Three patients were lost to follow-up
(1 patient in the 7-day group and 2 patients in the
3-day group). Another patient was dropped from
the study after randomization when a repeated
pregnancy test was positive. Seventy-three patients
completed the study. Thirty-five patients were
randomized to the 3-day group and 38 patients to
the 7-day group. The mean age of the 3-day group
was 21.8 (___5.5 years), compared with 21.3 (___4.5
years) in the 7-day group. There was no significant
differences among groups in age (P 0.65), gravid-
ity (P 0.16), or parity (P 0.09).
Follow-up PCR assays were obtained approxi-
mately 3 weeks after completion of therapy. There
was no significant difference (P 0.27) in follow-up
intervals between the 3-day (3.7 weeks) and the
7-day (4.2 weeks) groups. Of the 35 patients in the
3-day group, there were 2 treatment failures (effi-
cacy, 94%). The 7-day group had 2 treatment fail-
ures out of 38 patients (efficacy, 95%). There was
no significant difference in efficacy between the
two groups (Fisher’s exact test P 1.0). Table 2
provides descriptions of the 4 treatment failures.
Patients in the 7-day group took all their medi-
cation appropriately. Two patients in the 3-day
TABLE 3. Side-effect profile
Side effect 3 day % 7 day %
None 23 66 26 68
Nausea 8 23 8 21
Vomiting 5 14 3 8
Stomach upset 2 6 3 8
Headache 2 6 3 8
Diarrhea 3 2 5
group did not complete their medication. One pa-
tient took only 5 pills over a 3-week period instead
of 3 days in a row. This patient’s test of cure was
positive. The second patient took 4 pills over 2
days and did not take the 3rd day of pills due to
nausea. This patient’s test of cure was negative.
Thirty-four percent of patients in the 3-day
group and 32% in the 7-day group reported side
effects (P 1.0). The most common side effect was
nausea (Table 3).
DISCUSSION
Chlamydia trachomatis has a complex and long life
cycle. The elementary body (infectious particle)
attaches to and enters the endocervical cells. The
elementary body remains as a cytoplasmic inclu-
sion throughout its life cycle within the cell. Within
the inclusion body, noninfectious but metabolically
active reticulate bodies are formed. The reticulate
bodies condense to form elementary bodies. The
typical life cycle takes between 48 and 72 h to
complete. For an antimicrobial agent to be effec-
tive against chlamydia, it must be present over a
period of 2-3 days.6
Azithromycin is a new macrolide antibiotic
which has been shown to be as effective as a 7-day
course of doxycycline in the treatment of uncom-
plicated chlamydia infections of the uterine cervix.
Azithromycin is effective in treating chlamydia
with a single dose due to its long half-life (68 h) and
adequate tissue penetration.
6
Doxycycline is one of the current drugs of
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choice for the treatment of chlamydia cervicitis. It
is the drug to which all other therapeutic regimens
are compared. It is well absorbed by the gastroin-
testinal tract within 1-3 h and food does not impair
absorption. The serum half-life is 12-18 h after a
single dose and 18-22 h after several doses. A
single 200 mg oral dose achieves serum levels of 2.5
lag/ml and intravenous administration offers no
benefit over oral dosing. The mean inhibitory con-
centration (MIC) of chlamydia is 0.06 lg/ml. Doxy-
cycline is effectively distributed to the female
genital tract. 7 It is one of the most active agents
against chlamydia as demonstrated by in vitro sus-
ceptibility testing and human clinical trials. 8 A
large body of literature is available which demon-
strates that a 7-day course of doxycycline has a fail-
ure rate of 0-8% for uncomplicated chlamydia cer-
vicitis.9
A few reports have shown that shorter dosing
regimens of antibiotics are as effective in treating
chlamydia as the standard 7-day course of doxycy-
cline or erythromycin. Stature et al.1 compared a
3-day course of trimethoprin-sulfamethoxazole
(TMP-SMZ) with a 5-day course of tetracycline
and found 30 of 32 (94%) women cured in the
TMP-SMZ group and 27 of 29 (93%) cured in the
tetracycline group. Bowie et al. 11 compared the ef-
ficacy of several treatment regimens for lower geni-
tal tract chlamydia infections in women. They
made an interesting observation that of the 3
women who took only 3 days of ampicillin, all had
negative cultures. Also of interest is a study by
Levallois and Riouxlz in which they performed a
randomized, double-blind, placebo-controlled trial
of doxycycline for suction curettage abortion pro-
phylaxis. Seventy-five women who preoperatively
screened positive for chlamydia were randomized
into a prophylaxis and placebo group. Prophylaxis
consisted of 100 mg of doxycycline preoperatively
and a 200 mg dose postoperatively. In the prophy-
laxis group, only of 33 (3.0%) had signs or symp-
toms of post-abortal pelvic infection vs. 11 of 42
(26.2%) of women in the placebo group. Though
this study’s endpoint was post-abortal pelvic infec-
tion, a 1-day course of doxycycline significantly re-
duced the risk of infection in women with chla-
mydia infection.
We elected to perform a test of cure 3 weeks
following the completion of therapy. We chose 3
weeks instead of a longer time interval for the fol-
lowing reasons. First, we were concerned that the
longer the interval from completion of therapy to
test of cure, the greater the risk of reinfection and
losing the patient for follow-up, z,4,6 Second, after
reviewing the literature, we found that many stud-
ies, including the recommendations from the CDC,
use between 2 and 4 weeks for repeat testing,z,3-6
Workowski et al.6 studied the duration of detect-
ing chlamydia by PCR and tissue culture following
a 7-day course of doxycycline. They found that
chlamydia is eradicated immediately after treat-
ment as detected by tissue culture, but can be de-
tected up to week following therapy by PCR.
The major side effects of doxycycline in pa-
tients are related to gastrointestinal effects. We an-
ticipated that shortening the course of therapy
would reduce the side effects. However, there was
no significant reduction in side effects when com-
pared to the 7-day course of therapy. We believe
this demonstrates that side effects from doxycy-
clinc occur early in the course of therapy. Though
there was no difference in patient compliance in
this study, we believe patients off study protocols
are more likely to complete a 3-day course of
therapy than 7 days.
This study was designed as a preliminary study
to see if a 3-day course of doxycycline was a fea-
sible treatment option for chlamydia cervicitis.
Therefore, we chose a study design which could
identify a 25% difference between groups at a
power of 0.8 and a P-value of 0.05. For comparison,
it would take 280 patients (140 per treatment arm)
to perform a study which could identify a 10% dif-
ference between groups with a power of 0.8 and a
P-value of 0.05. Our institution does not have a
sexually transmitted disease population large
enough to perform a study of this magnitude in a
reasonable amount of time. We believed that if no
statistical difference was found between a 3- and a
7-day course of therapy, further study would be
warranted.
There were no statistically significant differ-
ences between groups in population demographics,
patient compliance, efficacy, or side effects when
comparing the 3-day and the 7-day study groups. A
3-day course of doxycycline appears to be as effec-
tive as a 7-day course of therapy for uncomplicated
chlamydia cervicitis. This report provides strong
preliminary data to support further investigation
with this treatment regimen.
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